Developing Novel Chemistries for the Microbiome Organ

Kaleido is the first company to develop novel chemistries to systematically drive functions of the microbiome organ. To date, microbiome therapeutic strategies have focused primarily on adding or subtracting bacteria. We seek to influence the trillions of microbes that already reside in the human body. We use chemistries to drive various outputs of the microbiome organ depending on the disease or condition.
  • MICROBIOME METABOLIC THERAPIES
  • FUNCTIONAL OUTPUTS
  • DISCOVERY & DEVELOPMENT MODEL

Kaleido’s Microbiome Metabolic Therapies (MMTs) drive functional outputs of the microbiome organ to treat disease and improve overall health. The company is advancing a pipeline of MMTs in multiple therapeutic areas.

The Microbiome

The human microbiome is community of trillions of microbes that live in and on us. In the past decade, there has been an exponential increase in data revealing the microbiome’s role in multiple areas of health and disease, including autoimmunity, oncology, neurobiology and metabolism. It is akin to the discovery of a new organ, with broad impacts on our ability to prevent and treat disease.

The Microbiome: An Important Frontier in Health & Medicine

Learn why the human microbiome is one of the most exciting fields of medicine, with far reaching implications for disease and health.